Pierre-Luc Etienne

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.2K citations

OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

Christophe Tournigand, Andrés Cervantes, Arié Figer et al. · Journal of Clinical Oncology · 2006 · 799 citations

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade et al. · Journal of Clinical Oncology · 2010 · 747 citations

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade et al. · Journal of Clinical Oncology · 2012 · 421 citations · Full text

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology · 2014 · 416 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +9